
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
p19 INK4D/CDKN2D CRISPR/Cas9 KO Plasmid (m) | sc-419613 | 20 µg | $397.00 |
Mouse Cdkn2d encodes p19 INK4D (CDKN2D), a cyclin-dependent kinase inhibitor that restrains cell-cycle progression by binding CDK4/6 and limiting cyclin D–dependent phosphorylation of RB, thereby enforcing the G1 checkpoint. p19 INK4D integrates signals from mitogenic and stress-responsive pathways to coordinate proliferation with differentiation, particularly in developing and adult tissues where precise control of cycling is required. Altered regulation of the INK4 family and the RB–E2F axis is broadly linked to dysregulated proliferation and genome instability, making CDKN2D a useful node for studying cell-cycle control in disease-relevant contexts. Cdkn2d perturbation is also leveraged to interrogate compensatory relationships among INK4 proteins and their impact on senescence-like programs and lineage commitment.
p19 INK4D/CDKN2D CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Cdkn2d gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Cdkn2d together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Cdkn2d open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish p19 INK4D/CDKN2D protein expression.
This CRISPR knockout system enables efficient generation of Cdkn2d-deficient cell models for investigation of p19 INK4D/CDKN2D signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.